Description
Pharmacological action
Pharmaceutical group: adaptogenic agent.
Pharmaceutical action: Pharmacological action – metabolic, restorative, adaptogenic, regenerating, detoxifying, immunomodulating, antiviral, genoprotective, antimalarial, antiparasitic.
The spectrum of effects obtained with the use of the drug is so wide that it can be classified as a systemic drug that detects and restores informational disorders (restoration of correct genetic replications), functional, metabolic, energetic connections in the body, activating regenerative, reparative processes at different levels. Such capabilities of the drug are due to a powerful antioxidant effect (blockade of the final stages of oxidative stress). It has a non-specific and specific antiviral effect.
Variety of biologically active compounds, approaching the chemical composition to the complex membrane structure of human cells, it determines the multivalence of the MilifeВ® effect on metabolic-endocrine-immune processes, exerting a corrective effect on all types of metabolism and homeostasis in general.
Represents the biomass of monoculture of the higher fungus Fusarium sambucinum, strain VSB 917. Contains low molecular weight oligopeptide compounds, alkaline oligopeptides, 18 amino acids, including all essential amino acids, which account for up to 45% of the total amino acids of the drug.
The carbohydrate composition of the drug includes biologically active polysaccharides (glycans: glucans and galactomannans, lentinan).
In addition, MilifeВ® contains oxamic, malic, citric, succinic and other organic acids.
The lipid fraction of the drug contains phospholipids, sterols, glycerides, fatty acids and ubiquinones.
More than 50% of the fatty acids that make up MilifeВ® are essential oils – linoleic and linolenic, which are not synthesized in the human body and must come from food.
MilifeВ® contains a complete complex of B vitamins.
MilifeВ® contains a balanced set of macro- and micronutrients in an easily digestible form of organic compounds and complexes.
From the first days of administration, the positive activity of MilifeВ® begins to manifest itself at the molecular-cellular level in those organs and systems that have the most profound and gross disorders.
Milife®, acting on the mesodiencephalic structures of the brain, finds the “Locus minoris” (“place of least resistance”) in the body and acts on it selectively and sequentially.
MilifeВ® has a general strengthening and adaptogenic effect, increases the body’s resistance to the effects of the endoecological environment, increases the body’s resistance to stressful effects, preventing secondary post-stress effects. Increases mental and physical performance, as well as accelerates recovery from stress and diseases of various etiologies. This is made possible thanks to the powerful antioxidant effect of the drug.
MilifeВ® enhances proliferative activity (division activity) in cells and controls the cell cycle, triggers an accelerated apoptosis system in defective cells, which slows down the accumulation of mutations.
MilifeВ® frees cells from genetically excessive (extrachromosomal) DNA as a result of increased vesicular traffic (intracellular and intercellular transport in membrane vesicles). The result of this is the suppression of defective ones and an increase in the accuracy of replication of existing sequences in DNA, which allows MilifeВ® to be used for the prevention of oncological processes and for the suppression of the progression of malignant cells during oncotherapy.
MilifeВ® has a bioregulating multidirectional effect, which can strengthen the weak, weaken the strong or leave the normal immune system response unchanged.
As a result of experimental studies and clinical trials, it was found that Milife® acts on immunocompetent organs, contributes to the normalization of indicators of both cellular and humoral immunity. It causes the effect of colony-stimulating factor in immunocompetent organs, increasing the renewal of lymphoid cells by 1.7–2.1 times. Restores the entire interleukin series (from IL-1 to IL-18). As an inducer of alpha, beta and gamma interferon, a tumor necrosis factor (alpha / beta), the drug increases the number of natural killers (CD16), increases the number of B lymphocytes, increases the immunoregulatory index (ratio of helpers and suppressors) due to an increase in cytotoxic T lymphocytes (CD8) and T-helpers (CD4).
Given the effect of MilifeВ® on immunocompetent organs and increased vesicular traffic, the neuroimmune system is able to recognize pathological changes in the cell and the cause of these changes, in particular the virus. The consequence of this is the specific and non-specific antiviral effect of the drug. MilifeВ® induces cellular and humoral immunity by increasing cytotoxic T-lymphocytes (CTLs), which recognize the presented antigens by restoring the function of the proteins of the main histocompatibility complex (MHC) and lyse infected cells. MilifeВ® has a direct virucidal effect, i.e. destroys the virus, acting directly on its structure, even if the virus is in latent form. Helps eliminate the virus by eliminating the cells that produce the virus. Against the background of the action of the drug, B-lymphocytes form a wide range of soluble antibodies that neutralize the virus and support the immune response by increasing the number of active B-lymphocytes with long-term memory and increasing the duration of persistent expression of the virus antigen. The drug even promotes the inactivation of the virus until the moment when it has a chance to infect new host cells. The antibodies formed mobilize the inflammation system, including the complement system, neutrophils and monocytes. Thus, even when antibodies do not directly neutralize the virus, there is the possibility that other effector functions of the antibodies will be enhanced through the use of an inflammation system. The drug does not allow the virus to acquire resistance properties and evolve.
A wide range of antiviral activity of the drug indicates the presence of pronounced immunological mechanisms of action, which is confirmed by studies conducted at the Institute of Epidemiology and Microbiology. N.F. Gamaleya and Research Institute of Virology and Epidemiology. Ivankovsky.
MilifeВ® has specific activity against Plasmodium vivax, Plasmodium falciparum and Plasmodium malariae both in the prophylactic regimen and when taking the drug 72 and 96 hours after infection.
The data on the high specific activity of MilifeВ® against Plasmodium vivax, Plasmodium falciparum and Plasmodium malariae are consistent with the pronounced antiviral and immunostimulating activity of MilifeВ® during experimental influenza infections, infections caused by encephalitis viruses and other viruses, and other viruses, (yellow fever, malaria, toxoplasmosis and leishmaniasis).
MilifeВ® has a hepatoprotective effect, normalizes impaired detoxification and protein-forming function of the liver due to the activation of many isoforms of cytochrome P450.
MilifeВ® does not contain doping components (Expert Opinion No. S068S of the Anti-Doping Center of May 24, 2008) and can be recommended for widespread use in sports medicine.
Based on the work performed, it can be stated that MilifeВ®, when applied on a course, restores the physical and mental performance of athletes, has a modeling effect on clinical, biochemical and immunological blood parameters.
Pharmacokinetics: After oral administration, the drug is rapidly absorbed. Maximum activity is achieved after 90 minutes. Bioavailability is almost complete. The degree of binding to plasma proteins is up to 6%, the volume of distribution is 1.8–1.9 l / kg.
The drug quickly penetrates the tissues, organs and biological fluids of the body – the heart muscle and heart valves, liver, spleen, adrenal glands, kidneys, gall bladder, pancreas, uterus, prostate gland, bones, abdominal and pleural cavities, saliva, sputum. MilifeВ® concentration in tissues and organs is higher than plasma concentration.
The drug is excreted mainly with urine (up to 70% within 72 hours) and partially with bile – up to 25%.
Indications
chronic fatigue syndrome and immune dysfunction
complex therapy for the treatment of viral and toxic liver lesions (including alcohol origin)
immunodeficiency and immunosuppression
complex therapy for the treatment of autoimmune diseases, autoimmune diabetes therapeutic and prophylactic agent for influenza, latent forms of herpes (6 types of herpes), chlamydial, ureaplasmosis infections with HIV and hepatitis C infections, as well as infections, caused by pathogens of yellow fever and malaria
conducting radiation and chemotherapy in cancer patients
period of preoperative preparation and postoperative rehabilitation
neuroendocrine disorders (mastopathy, ovarian dysfunction and cystic changes, uterine fibroids, endometriosis, various infertility) srdlm physical culture and sports (any age categories – from junior to veteran age) in training and competition cycles, in honors increasing agent efficiency and raises the threshold of fatigue
rehabilitation of sportsmen after injuries and at the exit from the “big” sports.
Contraindications
individual intolerance to the components of the drug
liver and kidney disease (terminal stages of liver cirrhosis and chronic renal failure.
Use during pregnancy and lactation
During pregnancy and during breastfeeding, based on the results of long-term clinical observations, a dose of 100 mg 3 times a day is recommended, and in case of intercurrent diseases (SARS, influenza, etc.) – 1 g 6 times in 3-4 days.
Special instructions
Based on 15 years of experience observing people of different sexes and ages who have taken MilifeВ®, The following results were obtained.
Normalization of the level of all indicators (clinical and biochemical) of blood was noted.
Normalization of T- and B-cell components of the immune system was noted.
A study of the hormonal profile showed a correlative effect of MilifeВ® on the level of pituitary hormones and ovarian hormones in the I and II phases of the menstrual cycle, a significant increase in progesterone in the ovulation phase of the menstrual cycle. An anovulatory cycle was not observed in any of the women of reproductive age.
The data obtained indicate reliable stabilization and normalization of the neurohormonal profile in the reproductive ring of the hypothalamus-pituitary-adrenal gland-ovaries, which allows recommending the drug MilifeВ® to girls of pre- and puberty in order to relieve the syndrome of psychoemotional lability, the formation and normalization of the menstrual cycle.
Ultrasound revealed a decrease in the size of the subserous-interstitially located fibromatous nodes up to their complete lysis, a small percentage of women had a “birth” of submucous located fibromatous nodes, the myometrium structure cellularity and cystic ovarian degeneration disappeared.
After taking the drug, a positive EEG dynamics was revealed in the form of normalization of the alpha rhythm, the appearance of zonal differences, the disappearance of paroxysmal changes during functional loads. The revealed positive EEG dynamics indicates normalization of the functional state of mesodiencephalic brain formations while taking MilifeВ® in more than 90% of those who took the drug.
Functional examination of cerebral vessels showed no signs of venous stasis, blood supply to the zones of the carotid arteries improved, vascular tone in the vertebrobasilar basin returned to normal. MilifeВ® improves microcirculation not only by restoring the rheological properties of blood, but also by improving blood supply directly to the vessel wall itself (in particular the epithelium).
MilifeВ® restores previously disturbed processes of neurohumoral regulation and myocardial energy resources, which is reflected in improved contractility, relaxation function and positive inotropic stimulation of the heart. The restoration of bioenergy processes improves the compensatory capabilities of the body, contributing to the work of the heart in a more economical mode.
In chronic latent forms of genital herpes and chlamydia, a massive exit of infectious agents from the cells was detected and their subsequent elimination, which is associated with the development of the body “short” immunity. This contributed to the restoration of the microscopic structure of the mucous and muscle fibers of smooth muscles.
The MilifeВ® preparation, when applied over a course of 21 days, increases the overall athletic performance of athletes by no less than 30%, which is reflected in an increase in running time to failure on a treadmill with stepwise increasing physical activity.
A powerful antioxidant effect of the drug was detected at the same time. Morphologically, this effect was expressed in stabilization of muscle mass against the background of mobilization of fats, while in the control group there were signs of maladaptation to similar loads in the form of a total decrease in three morphological parameters (body weight, muscle mass, fat mass).
MilifeВ® in case of course use prevents the increase of urea concentration in the blood of athletes (statistically significant by 17.8%), as well as a decrease in the level of hematocrit and lactate. An increase in the contractile ability of the myocardium and an improvement in the propulsive work of the heart were noted.
The circulatory system function was economized by increasing the ability of muscles to use oxygen and improving the ability to contract isotonically in the heart muscle.
Positive dynamics was noted on the part of the contractile ability of the myocardium and the phase structure of systole. The lengthening of the prediction period indicated an improvement in the ability of the myocardium to create the necessary tension for a powerful reduction. The reduced value of intraventricular pressure created the conditions for reducing stress in the wall of the left ventricle, which, together with reduced systolic indicators of the thickness of the posterior wall of the left ventricle and its size, contributed to a certain decrease in systolic meridional and circulatory stresses and an increase in the values ​​of the functioning index of structures. Evaluation of diastolic function showed an improvement in the ability of myocardiocytes to accumulate the necessary energy reserve.
Restores immunological reactivity in high-class athletes, which is expressed in the normalization of a reduced concentration of immunoglobulins A, M and G, normalizes the reduced level of complement components C3 and C4 due to exhausting physical exertion in athletes training for endurance.
Favorably affects cellular immunity (phagocyte activity, phagocytosis intensity, lysosome activity, monocyte activity, increases the number of T and B lymphocytes). Normalizes non-specific protection factors, such as the level of alpha-1-glycoprotein and alpha-2-glycoprotein, while the concentration of seromucoid and haptoglobin practically does not change.
Dosage and administration
Substance: for the preparation of a solution for the treatment of wound surfaces and trophic ulcers 1 g of the drug is diluted in 50 ml of distilled water.
Tablets: sublingually (absorb), after meals.
Capsules: by mouth, after meals.
In the process of studying the effect of the drug, two dosages were developed that affect the body systems and the body as a whole – 50 mg and 1 g.
The use of different dosages and their alternation is determined by specific preventive and therapeutic tasks. At a dose of 100 mg 3 times a day, broken bonds in the body are detected and restored at the molecular and submolecular level, subjectively, this is manifested by various clinical symptoms of a chronic pathology that a person has. At a dose of 1 g from 6 to 12 times a day, a positive effect on the pathological focus is directly carried out and defective cells are replaced, subjectively, the clinical manifestations are stopped.
The selection of the Milife® regimen is individual and depends on the initial status (immunological, neurohumoral, etc.).
Starting schedule for taking Milife®: 1. From 1 to 5 days: 100 mg 3 times a day.
2. From day 6 for 12 weeks: Monday, Tuesday, Wednesday – 100 mg 3 times a day Thursday, Friday, Saturday, Sunday – 1 g 3 times a day.
3. For women: 200 mg intravaginally, for 30 days (excluding menstruation days) from the 6th day of taking Milife®.
4. Cedar oil for 1 dessert spoon 1 time on the days of taking Milife® 1 g each (Thursday, Friday, Saturday, Sunday).
5. Exercise (activities).
After taking the starting regimen, the doctor decides on the need for further administration of Milife® according to an individual regimen.
For athletes and people who are actively involved in physical education, the starting schedule is the same, but in the pre-start and starting periods, the dose increases to 12 g / day (2 g 6 times). This scheme is approved by the Laboratory of Clinical Pharmacology and Anti-Doping Control of the Moscow Scientific and Practical Center for Sports Medicine.
Side effects
MilifeВ® at any dosage has neither carcinogenic, nor mutagenic, nor teratogenic, nor embryotoxic properties.
MilifeВ® does not contain xenobiotics, preservatives or any substances that lead to the development of allergic reactions.
In the course of detailed experimental studies of the drug, no side effects from its use were revealed.
Active ingredient
Mushroom Fusarium Biomass
Terms of sale from
pharmacies Without a prescription
dosage form
tablets
Appointment
Other
Milife, Russia
